Patents by Inventor Stephen T. Wrobleski

Stephen T. Wrobleski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20240002364
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: September 5, 2023
    Publication date: January 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: CHUNJIAN LIU, MICHAEL G. YANG, ZILI XIAO, LING CHEN, RYAN M. MOSLIN, JOHN S. TOKARSKI, DAVID S. WEINSTEIN, STEPHEN T. WROBLESKI
  • Sulfone pyridine alkyl amide-substituted heteroaryl compounds
    Patent number: 11787779
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: October 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20220356180
    Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 29, 2021
    Publication date: November 10, 2022
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20210253554
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 19, 2021
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • Sulfone pyridine alkyl amide-substituted heteroaryl compounds
    Patent number: 11021462
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 11021475
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski
  • Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 10781215
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 22, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, David S. Weinstein, Michael G. Yang
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20200071315
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Yanlei, Qingjie Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10526321
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Shuqun Lin
  • HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20190322672
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 24, 2019
    Inventors: Stephen T. Wrobleski, David S. Weinstein, Michael G. Yang
  • Tricyclic heterocyclic compounds useful as inhibitors of TNF
    Patent number: 10308652
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 4, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Gregory D. Brown, Shuqun Lin, Jingwu Duan, Zhonghui Lu, Murali T. G. Dhar, Hai-Yun Xiao, Andrew J. Tebben
  • Heterocyclic compounds useful as inhibitors of TNF
    Patent number: 10112944
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) —(CR3R3)1-4— or (ii) —(CR3R3)x-Y—(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: October 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lawrence R. Marcin, Stephen T. Wrobleski, T.G. Murali Dhar
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20180265504
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 20, 2018
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10000480
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: June 19, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9987266
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: June 5, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF
    Publication number: 20180111937
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 17, 2016
    Publication date: April 26, 2018
    Inventors: Stephen T. WROBLESKI, Gregory D. BROWN, Shuqun LIN, Jingwu DUAN, Zhonghui LU, Murali T.G. DHAR, Hai-Yun XIAO, Andrew J. TEBBEN
  • HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF
    Publication number: 20180072728
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) —(CR3R3)1-4— or (ii) —(CR3R3)x-Y—(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 15, 2018
    Inventors: Lawrence R. MARCIN, Stephen T. WROBLESKI, Murali T.G. DHAR
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES
    Publication number: 20170209426
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9663467
    Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: RE47929
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang